Overcoming challenges in the management of schizophrenia

International Journal of Psychiatry in Clinical Practice

Volumn 3, Issue 1, 1999, Pages 11-15

  Kopala, Lili C ^a   Baldwin, David ^b   Weiden, Peter ^c   Hellewell, Jonathan S E ^d  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^d TRAFFORD GENERAL HOSPITAL   (United Kingdom)

Author keywords

Atypical antipsychotics; Concordance; Improved tolerability; Patient satisfaction; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

DRUG EFFICACY; DRUG SPECIFICITY; DRUG TOLERABILITY; HUMAN; NEGATIVE SYNDROME; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

EID: 0032904737     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.3109/13651509909024753     Document Type: Review

References (36)

1. Mōller H-J, von Zerssen D (1995) Course and outcome of schizophrenia. In: Schizophrenia (eds SR Hirsch, D Weinberger). 106-27. Blackwell Science Inc, Oxford.
2. Johnstone EC, Crow TJ, Johnson AL et al (1986) The Northwick Park Study of first episode schizophrenia. I: Presentation of the illness and problems relating to admission. Br J Psychiatry 148: 115-20.
3. Loebel AD, Lieberman JA, Alvir JMJ et al (1992) Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 149: 1183-8.
4. McGorry PD, Edwards J, Mihalopoulos C et al (1996) EPPIC: An evolving system of early detection and optimal management. Schizophr Bull 21: 305-26.
5. Davies JM, Janicak P, Singla A et al (1993) Maintenance antipsychotic medication. In: Antipsychotic drugs and their side-effects (ed. TRE Barnes) 183-203. Academic Press, London.
6. Wiersma D, Nienhuis FJ, Slooff CJ, Giel R (1998) Natural course of schizophrenic disorders: a 15-year follow-up of a Dutch incidence cohort. Schizophr Bull 24: 75-85.
7. Whitehorn D, Rui Q, Frankland B et al (1998) Early psychosis program in Nova Scotia; symptom presentation and treatment response. 48th Annual Meeting of the Canadian Psychiatric Association, Halifax, Nova Scotia, September 15-18, 1998.
8. Ruscher SM, de Wit R, Mazmanian D (1997) Psychiatric patients' attitudes about medication and factors affecting noncompliance. Psychiatr Serv 48: 82-5.
9. Kemp R, David A (1996) Psychological predictors of insight and compliance in psychotic patients. Br J Psychiatry 169: 444-50.
10. Hoge SK, Appelbawe PS, Lawlor T et al (1990) A prospective, multicenter study of patients' refusal of antipsychotic medication. Arch Gen Psychiatry 47: 949-56.
11. Young JL, Zonana HV, Shepler L (1986) Medication non-compliance in schizophrenia: codification and update. Amer Acad Psychiatry Law 14: 105-22.
12. Amt J, Skarsfeldt T (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18: 63-101.
13. Kane J, Honigfield G, Singer J et al (1988) Clozapine for the treatment resistant schizophrenic. Arch Gen Psychiatry 45: 789-96.
14. Pirmohamed M, Park K (1997) Mechanism of clozapine-induced agranulocytosis. CNS Drugs 7: 139-58.
15. Conley R (1998) Optimizing treatment with clozapine. J Clin Psychiatry 59 (Suppl 3): 44-8.
16. Chouinard G, Jones B, Remington G et al (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13: 25-40.
17. Peuskens J (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 166: 712-26.
18. Davies A, Adena MA, Keks NA et al (1998) Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety. Clin Ther 20: 58-71.
19. Tollefson GD, Beasley CM Jr, Tran PV et al (1997) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154: 457-65.
20. Zimbroff DL, Kane JM, Tamminga CA et al (1997) Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 154: 782-91.
21. Arvanitis LA, Miller BG (1997) Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 42: 233-46.
22. th Congress of the European College of Neuropsychopharmacology, Paris, France, 31 October-4 November 1998.
23. King DJ (1998) Drug treatment of the negative symptoms of schizophrenia. Eur Neuropsychopharmacol 8: 33-42.
24. Casey DE (1997) The relationship of pharmacology to side-effects. J Clin Psychiatry 58 (Suppl 10): 55-62.
25. Kapur S, Zipursky RB, Remington G et al (1998) 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 155: 921-8.
26. Birchwood M, McGorry P, Jackson H (1997) Early intervention in schizophrenia. Br J Psychiatry 170: 2-5.
27. Van Putten T, May PR, Marder SR, Wittmann LA (1981) Subjective response to antipsychotic drugs. Arch Gen Psychiatry 38: 187-90.
28. Van Putten T, May PR, Marder SR (1984). Response to antipsychotic medication: the doctor's and the consumer's view. Am J Psychiatry 141: 16-9.
29. Awad AG, Voruganti LN, Heslegrave RJ, Hogan TP (1996) Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome. Int Clin Psychopharmacol 11 (Suppl 2): 55-9.
30. Marinker M (1997) Writing prescriptions is easy. Br Med J 314: 747-8.
31. Williams S, Weinman J, Dale J, Newman S (1996) Expectations: a comparison between general practice patients with and without mood disorder. Prim Care Psychiatry 2: 229-35.
32. Joos SK, Hickman DH, Borders LM (1994) Patients' desires and satisfaction in general medicine clinics. Public Health Reports 108: 751-9.
33. Hellewell JSE, Cantillon M (1998) Antipsychotic tolerability: the attitudes and perceptions of medical professionals, patients and caregivers towards the side-effects of antipsychotic therapy. Abs P.2.109. Eur Neuropsychopharmacol 8 (Suppl 2): S248.
34. Hellewell JSE, Kalali AH, Langham SJ, McKellar J (1998) Patients' satisfaction and acceptability of long-term treatment with 'Seroquel': results of an international study. Abs P.2.108. Eur Neuropsychopharmacol 8 (Suppl 2): S248.
35. Carroll A, Mortimer A (1998) Perceived needs in patients with chronic schizophrenia: Their relationship to negative symptoms and to insight. Schizophrenia Res 29: 191.
36. Budd R, Hughes IC, Smith JA (1996) Health beliefs and compliance with antipsychotic medication. Br J Clin Psychol 35: 393-7.